基因组学合作与授权协议（2018-2025）

"基因组学合作与许可协议" 报告全面深入分析了全球领先的生物製药公司签署的基因组学相关协议，并提供前所未有的资讯取得管道。

这份经过全面修订和更新的报告详细介绍了2018年至2025年间的基因组学相关协议。

本报告深入分析了企业签署基因组学相关协议的原因和方式。这些协议通常包含多个组成部分，从合作研发开始，最终实现成果的商业化。

本报告涵盖合作、开发、研究和授权等内容。

本报告列出了自2018年以来宣布的639项基因组学相关交易，并提供了可用的财务条款以及相关方披露的实际基因组学合作在线记录的链接。此外，在条件允许的情况下，记录还包括公司及其合作伙伴向美国证券交易委员会提交的合约文件。

本报告的引言概述了基因组学相关交易。

第一章概述了本报告。

第二章概述了自 2018 年以来基因组学相关交易的趋势。

第三章概述了自 2018 年以来主要的基因组学相关交易，并依交易额列出。

第四章提供了基因组学相关交易中最活跃的 25 家公司的完整列表，并附有简要概述，随后提供了基因组学相关交易和公开合约文件的完整列表。

第五章对自 2018 年 1 月以来已完成或已宣布的、且有公开合约文件的基因组学相关交易进行了全面深入的审查。

第六章对自2018年1月以来已完成或宣布的基因组学合作交易进行了全面深入的回顾。本章以具体的基因组学技术类型进行组织。

报告还包含大量表格和图表，展示了自2018年以来基因组学相关交易的趋势和活动。

此外，我们还提供了一个全面的交易目录，依公司名称（A-Z）、交易类型和治疗靶点进行分类。每个交易标题都透过网路连结指向交易记录的线上版本，并在可用的情况下指向协议文件，以便根据需要轻鬆存取每个文件。

主要优势

基因体学合作与授权协议报告为读者提供以下主要优势：

• 了解 2018 年及以后的交易趋势
• 查看基因体学相关的合作与授权协议
• 基准分析 - 确定交易市场价值
• 财务条款 - 首付款、里程碑付款、特许权使用费
• 依公司（A-Z）、协议类型和治疗领域分类的合约目录
• 以交易价值排名的热门交易
• 最活跃的交易撮合者
• 确定每笔交易的资产详情和合约条款
• 存取合约文件 - 深入了解交易结构
• 尽职调查 - 评估拟议交易条款对合作公司的适用性
• 节省数百小时的研究时间

范围

• "基因组学合作与许可协议" 报告旨在帮助读者深入了解全球生物製药公司的基因组学趋势和合约结构。

基因体学合作与授权协议包括：

• 生物製药产业的基因组学交易趋势
• 製药和生物技术公司基因组学交易记录目录
• 依价值排名的主要基因组学交易
• 最活跃的基因组学授权协议公司
• "基因组学合作与许可协议" 提供对可用协议记录的全面访问，包括合约文件（如有）。

分析合约有助于对以下内容进行尽职调查：

• 合约具体授予或选择哪些权利？
• 合约实际授予合作公司哪些权利？
• 授予哪些独家权利？
• 交易的付款结构是什么？
• 销售和付款如何审计？
• 合约期限是多久？
• 合约的关键条款是如何定义的？
• 知识产权（IPR）如何处理与归属？
• 谁负责商业化？
• 谁负责开发、供应和生产？
• 如何管理保密性和资讯揭露？
• 如何解决争议？
• 在什么情况下可以终止协议？
• 如果所有权发生变更，会发生什么事？
• 如何约定转让许可和分包条款？
• 贵公司要求哪些标准条款？
• 哪些标准条款会因交易对手和交易类型而异？
• 贵公司必须在哪个司法管辖区管辖其合约？

目录

摘要整理

第一章：引言

第二章：基因体学交易趋势

• 引言
• 历年基因体学交易
• 最活跃的基因组学交易商
• 依交易类型划分的基因组学交易
• 依治疗领域划分的基因体学交易
• 依行业划分的基因组学相关交易
• 基因体学交易条款
  • 基因体学交易的关键价值因素
  • 基因组学交易的预付款
  • 基因组学交易的里程碑付款
  • 基因组学特许权使用费率

第三章：基因体学的关键要素交易

• 引言
• 依价值排名的基因组学相关顶级交易

第四章 - 最活跃的基因组学经销商

• 引言
• 最活跃的基因组学经销商
• 最活跃的基因组学经销商公司简介

第五章：基因组学合约交易目录

• 引言
• 基因组学合约交易目录

第六章：依技术类型划分的基因体学交易

• 交易目录
• 依公司划分的基因组学交易目录 (AZ)
• 依交易类型划分的基因组学交易目录
• 依治疗领域划分的基因体学交易目录
• 交易类型定义
• 关于研究公司
• 当前合作伙伴
• 当前协议
• 近期合作伙伴报告标题

Genomic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the genomic deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of genomic deals from 2018 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter genomic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 639 genomic deals announced since 2018 including financial terms where available including links to online deal records of actual genomic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of genomic dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in genomic dealmaking since 2018.

Chapter 3 provides an overview of the leading genomic deals since 2018. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in genomic dealmaking with a brief summary followed by a comprehensive listing of genomic deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of genomic deals signed and announced since Jan 2018, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of genomic partnering deals signed and announced since Jan 2018. The chapter is organized by specific genomic technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in genomic deal making since 2018.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Genomic Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2018
• Browse genomic collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Genomic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of genomic trends and structure of deals entered into by leading biopharma companies worldwide.

Genomic Collaboration and Licensing Deals includes:

• Trends in genomic dealmaking in the biopharma industry
• Directory of genomic deal records covering pharmaceutical and biotechnology
• The leading genomic deals by value
• Most active genomic licensing dealmakers
• Genomic Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in genomic dealmaking

• 2.1. Introduction
• 2.2. Genomic deals over the years
• 2.3. Most active genomic dealmakers
• 2.4. Genomic deals by deal type
• 2.5. Genomic deals by therapy area
• 2.6. Genomic deals by industry sector
• 2.7. Deal terms for genomic deals
  • 2.7.1 Genomic deals headline values
  • 2.7.2 Genomic deal upfront payments
  • 2.7.3 Genomic deal milestone payments
  • 2.7.4 Genomic royalty rates

Chapter 3 - Leading genomic deals

• 3.1. Introduction
• 3.2. Top genomic deals by value

Chapter 4 - Most active genomic dealmakers

• 4.1. Introduction
• 4.2. Most active genomic dealmakers
• 4.3. Most active genomic deals company profiles

Chapter 5 - Genomic contracts dealmaking directory

• 5.1. Introduction
• 5.2. Genomic contracts dealmaking directory

Chapter 6 - Genomic dealmaking by technology type

• Deal directory
• Deal directory - Genomic deals by company A-Z
• Deal directory - Genomic deals by deal type
• Deal directory - Genomic deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Genomic deals since 2018
• Figure 2: Active genomic dealmaking activity - 2018 - 2025
• Figure 3: Genomic deals by deal type since 2018
• Figure 4: Genomic deals by therapy area since 2018
• Figure 5: Genomic deals by industry sector since 2018
• Figure 6: Genomic deals with a headline value
• Figure 7: Genomic deals with an upfront value
• Figure 8: Genomic deals with a milestone value
• Figure 9: Genomic deals with a royalty rate value
• Figure 10: Top genomic deals by value since 2018
• Figure 11: Most active genomic dealmakers 2018 - 2025
• Figure 12: Genomic deals by technology type since 2018